Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE REGULATORY NEWS IN BRIEF
February 12, 2001
-
ARCHIVE Asahi Chemical, Janssen-Kyowa to Make Utmost Efforts to Expand Japan's 1st SNRI Market
February 12, 2001
-
ARCHIVE NDA Review System Should Be Reformed as Part of Administrative Reform: New ELD Director
February 12, 2001
-
ARCHIVE Demographic Estimates for 2000 Show More Births: Koseisho
February 12, 2001
-
ARCHIVE EMA Proposes Measures to Encourage Use of Generics
February 12, 2001
-
ARCHIVE Korosho to Issue Notification in May to Introduce CTD
February 12, 2001
-
ARCHIVE Record-low Population Growth Rate Marked: Nat'l Census
February 12, 2001
-
ARCHIVE Senshu Yakuhin Restarts Business as Subsidiary of Kuraya Sanseido
February 12, 2001
-
ARCHIVE Kemporen Calls For Elimination of Financial Contribution to Elderly Healthcare
February 12, 2001
-
ARCHIVE 39 Monodrugs, 2 Combination Drugs Designated: Quality Reevaluation
February 12, 2001
-
ARCHIVE Mochida to Prevail through R&D, Alliance, Emphasis on Results
February 12, 2001
-
ARCHIVE Keisansho to Promote Healthcare Services as Industry
February 12, 2001
-
ARCHIVE REGULATORY NEWS IN BRIEF -2-
February 12, 2001
-
ARCHIVE Dainippon to Withdraw Aleviatin Fine Granules
February 12, 2001
-
ARCHIVE Drug Makers Must Assume Full Responsibility for Their Products
February 12, 2001
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 12, 2001
-
ARCHIVE Bayer Yakuhin, Meiji Seika to Comarket Ciproxan
February 12, 2001
-
ARCHIVE Japan Not to Introduce Inactivated Vaccine against Polio
February 12, 2001
-
ARCHIVE Combination Therapy with Protopic, Steroid Reported: Fujisawa Seminar
February 12, 2001
-
ARCHIVE Kyorin Establishes Subsidiary to Gain Foothold in US Market
February 12, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…